Molecule in Medical Technology

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

... drug discovery company developing small molecule disease-modifying treatments for Alzheimer's, has ... Ph.D., J.D. "Our combination of novel, small molecule drug candidates and biologically-relevant ... leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that ...

USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic

... program is to show proof of principle that a new molecule is a viable candidate for expanded clinical ... to help propel the manufacturing of this novel molecule toward Phase 1 clinical trials." "We are in ... toxicity therapies for cancer, has licensed the molecule from USC . The technology is covered under U.S. ...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

... pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical ... US$500 million. VA106483 is a novel small molecule drug candidate that exerts its effect directly in ... has been developed by Vantia based on its small molecule drug development expertise and is the first of ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

... cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B-cells. Ofatumumab also binds to the large loop of the CD20 molecule. The CD20 molecule is a key target in CLL therapy because it is ...

Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

... Small molecule Stem Cell Modulator Administered in Dual Cord ... in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase ... the initial step in our approach - using a small molecule to treat cells ex vivo but creating an in vivo ...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

... on cancer stem cells. TRC102 is a small molecule inhibitor of base excision repair that reverses ... and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in ... cancer patients in January, 2008. TRC102, a small molecule that reverses resistance to chemotherapeutics, ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

... cells. A Phase 1 clinical trial to evaluate this molecule against multiple types of solid tumors has been ... and in pathology. Dendreon has synthesized small molecule agonists including D3263 that activate the TRPM8 ... is also developing an orally-available small molecule that targets TRPM8 that could be applicable to ...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

... advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8 (a ... and in pathology. Dendreon has synthesized small molecule agonists including D3263 that activate the TRPM8 ... also is developing an orally-available small molecule that targets TRPM8 that could be applicable to ...

Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting

... new data on recent advances of its small molecule anticancer agents during a symposium and several ... April 19, 2009: 8:00 AM CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by ... of CX-4945 a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase I ...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

... Oral NKTR-118 combines Nektar's advanced small molecule polymer conjugate technology platform with ... important potential advance for many other small molecule therapies. "NKTR-118 demonstrates that our ... technology can potentially create new small molecule drugs with optimal physicochemical and ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... is a first-in-class, orally administered small molecule anticancer agent that delivers highly selective ... studies. "CX-4945 is a breakthrough molecule for Cylene," said Dr. William Rice, President and ... inhibitor CX-4945 is a first-in-class small molecule that has been optimized to selectively inhibit ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B cells.(4) This epitope is different from the ... available or in development.(5) The CD20 molecule is a key target in CLL therapy because it is ...

VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology

... "We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, ... into a clinical development company with a novel molecule that may have broad application in the treatment of cancer." VTX-2337 is a small molecule TLR8 agonist that is expected to be used in ...

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis

... of this condition. SB1518 is a small molecule JAK2-selective kinase inhibitor which has high ... target-driven approach to innovative small molecule therapies for cancer is built on a profound ... and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading ...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

... growth and survival. It is a first-in-class small molecule inhibitor of NAE. Both clinical and non-clinical ... MLN4924 MLN4924 is a first-in-class small molecule inhibitor of NAE, a new target discovered by ... relationship of MLN4924, a novel small molecule inhibitor of Nedd8-activating enzyme, in human ...

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

... safety profile of SB1518. SB1518 is a small molecule JAK2-selective kinase inhibitor which has high ... approach to developing innovative small molecule therapies for cancer is built on a profound ... and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading ...

St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy

... in the repair of DNA damaged by irradiation. The molecule exerted its effect in small quantities, and ... in turn, activates other proteins by attaching a molecule called phosphate to them in a process called ... they can build upon as they try to modify the molecule to enhance its potency and specificity and move ...

Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged

... scientific and public attention as a longevity molecule that allegedly mimics the effects of a calorie-restricted diet, the science surrounding this molecule has taken a dramatic turn in recent months, ... Aug 9; 102(32):11278-83] Nor does a singular molecule such as resveratrol appear to work as well as ...

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

... a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, ... initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ... focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal ...

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors

... inhibitors as well as isoform-selective small molecule PI3 kinase inhibitors. The scaffold also allows ... and development company focused on small molecule modulators of the PI3 kinase and PTEN ... cancer patients. SF1126, is a proprietary small molecule conjugate containing a pan-PI3K inhibitor that ...

Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone

... TELK ) announced today that its novel small molecule proteasome inhibitor program met a preclinical ... developing and commercializing novel small molecule drugs to treat serious diseases. The company's ... of drug candidates resulting from the small molecule proteasome inhibitor program described above, ...

ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease

... clinical trial on Exebryl-1(R), a novel small molecule drug targeting toxic beta-amyloid protein ... of Exebryl-1(R). Exebryl-1(R) is a novel small molecule drug developed at ProteoTech from its unique library of small molecule compounds designed to target specific amyloid ...

Pulmo BioTech Inc. Completes Bio-Distribution Studies

... of the lungs. Molecular Imaging uses a molecule designed to bond specifically to certain parts of ... of the vascular system of the lungs. Because the molecule (code named DFH-12) is tagged with ... in- vivo studies have shown that the molecule is predominantly retained in the lungs 30 minutes ...

Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells

... temporary 'knock down' approaches based on small molecule inhibitors, antibodies, antisense or RNAi." ... have initiated programs to develop small molecule or monoclonal antibody approaches to block the binding of HIV to CCR5. However, a small molecule or antibody approach requires the constant ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... In a poster presentation entitled "A potent small molecule PIM kinase inhibitor with in vivo oral ... a model that allowed for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as ... 13 8:45 a.m.-10 a.m. #744 - A potent small molecule PIM ...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

... "The promise of NKTR-102 and our small molecule PEGylation platform is capturing a great deal of ... invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is ... and lung cancers. By applying Nektar's small molecule PEGylation technology to irinotecan, NKTR-102 may ...

Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO

... phase 1 clinical trial of XL184, a novel small molecule inhibitor of MET, VEGFR2, and RET, in patients ... The phase 1 results of XL184, the first such molecule in this class also to inhibit the oncogenic MET ... the discovery and development of novel small molecule therapeutics for the treatment of cancer and ...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

... Enables First-Ever PEGylation of a Small molecule with Demonstrated Therapeutic ... The study also demonstrates that Nektar's small molecule PEGylation technology produced an increase in ... represent a major advancement for our small molecule PEGylation platform," said Howard W. Robin, ...

Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients

... Single molecule with Dual Mechanism May Offer Novel Approach to ... and angiotensin (AT1) receptor blockade -- in one molecule to treat high blood pressure. "We are very ... to discovering and developing novel small molecule therapeutics to address significant medical ....

ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354

... trial of CCX354, an orally-available, novel small molecule compound designed to specifically target the CCR1 ... the discovery and development of up to six small molecule drug candidates across four targets ... chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, ...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

... constipation. Nektar's advanced small molecule PEGylation technology has been shown to reduce ... used to enhance oral bioavailability for a small molecule drug," said Timothy A. Riley, Ph.D., Vice ... drug combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a ...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

... developed using Nektar's innovative small molecule PEGylation technology platform. NKTR-102 ... our confidence in the potential of our small molecule PEGylation technology platform to improve the ... invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is ...

InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update

... the combination of ITMN-191 with other small molecule compounds." ITMN-191 Program Update - Clinical, ... will investigate the combination of various small molecule compounds for the treatment of patients suffering ... of future combination studies using small molecule HCV compounds of different mechanisms of action. ...

Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer

... generate innovative and important PEGylated small molecule therapeutics. Based on our positive Phase 1 study ... invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is ... and lung cancers. By applying Nektar's small molecule PEGylation technology to irinotecan, NKTR-102 may ...

Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer

... regimen containing erlotinib. XL184 is a small molecule that simultaneously inhibits the MET, RET ... XL184 is a novel, orally administered, small molecule anticancer compound that in preclinical models ... the discovery and development of novel small molecule therapeutics for the treatment of cancer and ...

XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis

... to its pre-clinical Hepatitis C virus (HCV) small molecule program at HEP DART 2007, an international ... "Mechanistic Characterization of Potent Small molecule HCV Inhibitors that Target NS5A" describes a ... entitled "Pharmacologic Evaluation of Novel Small molecule HCV Inhibitors Affecting NS5A-dependent ...

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

... with TG101348, A JAK2 Selective Small molecule Inhibitor, in the Presence of ... Tam -- TG101348: A Dual Acting JAK2/FLT3 Small molecule Kinase Inhibitor for the Treatment of AML -- ... San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular ...

The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh

... focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that ... and chemistry technology to create novel small molecule libraries, and then rapidly screen these ... focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that ...

Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting

... developing and commercializing novel small molecule drugs to treat serious diseases. The company's ... are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the ... the rapid and efficient discovery of small molecule drug candidates. Additional information is ...

Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans

... Phase I Clinical Trial of Proprietary siRNA molecule in Acute Renal ... AKIi-5 is a synthetic, chemically modified siRNA molecule discovered and patented by Quark that has ... AKIi-5 is a synthetic, chemically modified siRNA molecule designed to temporarily inhibit the expression of ...